$MSP Recovery (LIFW.US)$
4: Statement of changes in beneficial ownership of securities-10% Owner Palantir Technologies Inc.

$Singular Genomics (OMIC.US)$
Singular Genomics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deerfield Mgmt IV, L.P.(6.66%),Deerfield Private Design Fund IV, L.P.(6.66%), etc.
SEC·

$Edesa Biotech (EDSA.US)$
Edesa Biotech’s Founder Makes Strategic Investment in the Company
Edesa Biotech (Nasdaq:EDSA) announced a strategic investment agreement with an entity affiliated with its CEO and Founder, Par Nijhawan, MD, for up to $5.0 million, including an immediate investment of $1.5 million. The investment involves purchasing Series A-1 Convertible Preferred Shares at $10,000 per share, convertible into common shares at $3.445, and warrants exercisable for 75% of the ...

$Lottery.com (LTRY.US)$
Receives Notice of Non-Compliance From Nasdaq
On October 28, 2024, Lottery.com Inc., a company listed on the Nasdaq Stock Market, received a notice from Nasdaq's Listing Qualifications staff indicating that the company's Market Value of Publicly Held Shares (MVPHS) had fallen below the minimum requirement of $5 million as stipulated by Nasdaq Listing Rule 5450(b)(1)(C). The company has been granted a 180-day grace period, until April 28, 2025, to regain compliance. Dur...

$CVRx Inc (CVRX.US)$
CVRx Reports Third Quarter 2024 Financial and Operating Results
Positive
▪️Revenue growth of 27% YoY to $13.4 million
▪️U.S. Heart Failure revenue increased 30% to $12.2 million
▪️Active implanting centers grew 31% to 208
▪️Hospital reimbursement increased from $17-23K to $43K per procedure
▪️Secured Category I CPT codes for improved reimbursement
▪️Strong cash position of $100.2 million
▪️Gross margin maintained at 83%
Negative
▪️Net loss increased to $13.1 mil...

$CVRx Inc (CVRX.US)$
CVRx Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(17.0%),Johnson & Johnson Innovation-JJDC, Inc.(17.0%)

$Lixte Biotechnology (LIXT.US)$
We are offering on a reasonable best efforts basis up to 1,895,734 units (“Units”), each consisting of one share of common stock, par value $0.0001 per share (“common stock”) or one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrant”) and one and one-quarter (1.25) common stock purchase warrants to purchase one share of common stock (each, a “Common Warrant”) at an assumed public offering price of $2.11 per Unit, which was the c...

$ALX Oncology (ALXO.US)$
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...